May 2 (Reuters) - Novartis AG:
* HEALTH CANADA APPROVES KISQALI™ FOR THE TREATMENT OF HR-POSITIVE AND HER2-NEGATIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH LETROZOLE AS AN INITIAL ENDOCRINE-BASED THERAPY Source text for Eikon: Further company coverage: